Vyndamax (tafamidis) (Tafamidis CAPSULE, LIQUID FILLED) 61 mg/1

Vyndamax (tafamidis) is an oral transthyretin (TTR) stabilizer manufactured by Pfizer and FDA-approved for treating hereditary ATTR amyloidosis (hATTR) cardiomyopathy and wild-type ATTR cardiomyopathy (ATTR-CM). It received orphan drug designation for this rare, progressive cardiac condition. Vyndamax represents a breakthrough in cardiology for patients with life-threatening amyloid-related heart disease.

Strength

61 mg/1

Pack Size

30 BLISTER PACK in 1 CARTON (0069-8730-30) / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0069-8730-

Manufacturer / TM Owner

Pfizer

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Vyndamax is indicated for patients with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM) and wild-type ATTR cardiomyopathy (wtATTR-CM), rare progressive diseases where abnormal transthyretin protein deposits in the heart, causing restrictive cardiomyopathy, conduction abnormalities, and heart failure. The drug targets a specific patient population with confirmed ATTR cardiomyopathy diagnosis, typically presenting with dyspnea, fatigue, and reduced cardiac function. Vyndamax works by stabilizing transthyretin tetramers, preventing dissociation and subsequent amyloid fibril formation. This mechanism slows disease progression, preserves cardiac function, and improves clinical outcomes. The drug is particularly beneficial for patients with early-to-intermediate stage disease who have not yet developed advanced heart failure, offering disease-modifying therapy for this otherwise progressive and fatal condition.

Side Effects

Common side effects of Vyndamax include gastrointestinal disturbances, peripheral edema, and arthralgia. Serious adverse events may include worsening heart failure, syncope, and conduction abnormalities. Patients require baseline and periodic cardiac monitoring including echocardiography and electrocardiography. Laboratory monitoring for liver and renal function is recommended, particularly during initial therapy. Ophthalmologic examination may be warranted given TTR's role in ocular amyloidosis. Healthcare providers should monitor for signs of disease progression and adjust supportive cardiac therapies accordingly. Adverse event reporting and close clinical follow-up are essential for optimizing patient outcomes.

Precautions & Warnings

Vyndamax is contraindicated in patients with hypersensitivity to tafamidis or excipients. Caution is advised in patients with severe hepatic or renal impairment, as dose adjustments may be necessary. Pregnancy category data should be reviewed; use only if benefits outweigh risks. Pediatric safety and efficacy have not been established. Patients with advanced NYHA Class IV heart failure may have limited benefit. Concurrent use with other TTR stabilizers is not recommended. Regular cardiac assessment is mandatory, especially in patients with baseline conduction abnormalities. Patients should maintain consistent dosing schedules and report symptoms of worsening heart failure, syncope, or palpitations immediately to healthcare providers.

Avoid Interactions

Vyndamax has minimal significant drug-drug interactions due to its mechanism of action. However, caution is advised with medications affecting cardiac conduction or hemodynamics. NSAIDs should be used cautiously due to potential renal effects and fluid retention. Warfarin and other anticoagulants may require monitoring as tafamidis may displace protein-bound drugs. Concurrent use with other investigational TTR-targeting agents is not recommended. Patients should inform healthcare providers of all medications, supplements, and herbal products. No specific food interactions have been identified, but consistent administration timing is recommended for optimal efficacy.

Frequently Asked Questions

Vyndamax is used to treat hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM) and wild-type ATTR cardiomyopathy (wtATTR-CM), rare progressive heart diseases caused by abnormal transthyretin protein deposits. It stabilizes transthyretin tetramers to slow disease progression and preserve cardiac function. Vyndamax is indicated for patients with confirmed ATTR cardiomyopathy diagnosis.

Vyndamax is administered orally as a capsule, typically at a dose of 80 mg once daily. The capsule should be swallowed whole with water and can be taken with or without food. Patients should maintain consistent dosing schedules and follow their healthcare provider's instructions regarding administration.

Common side effects include gastrointestinal symptoms, peripheral edema, and joint pain (arthralgia). Most side effects are mild to moderate and manageable. Patients should report any persistent or severe symptoms to their healthcare provider, particularly those related to cardiac function or worsening heart failure.

Vyndamax is manufactured by Pfizer, a leading global pharmaceutical company. Pfizer developed tafamidis as a disease-modifying therapy for ATTR amyloidosis.

Yes, Vyndamax received FDA orphan drug designation for hereditary ATTR amyloidosis with cardiomyopathy. Orphan drug status recognizes treatments for rare diseases affecting fewer than 200,000 people in the United States. This designation provides regulatory incentives and support for drug development in rare disease populations.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.